Skip Navigation LinksHome > March 1, 2014 - Volume 65 - Issue 3 > Efficacy and Safety of an Extended Nevirapine Regimen in Inf...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000052
Epidemiology and Prevention

Efficacy and Safety of an Extended Nevirapine Regimen in Infants of Breastfeeding Mothers With HIV-1 Infection for Prevention of HIV-1 Transmission (HPTN 046): 18-Month Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Fowler, Mary Glenn MD, MPH*; Coovadia, Hoosen MD; Herron, Casey M. MS; Maldonado, Yvonne MD§; Chipato, Tsungai MBChB; Moodley, Dhayendre PhD; Musoke, Philippa MBchB, PhD#; Aizire, Jim MBChB, MS#; Manji, Karim MBBS**; Stranix-Chibanda, Lynda MBChB, MMed††; Fawzi, Wafaie MD‡‡; Chetty, Vani B Tech; Msweli, Lindiwe BA; Kisenge, Rodrick PhD**; Brown, Elizabeth ScD; Mwatha, Anthony MS; Eshleman, Susan H. MD*; Richardson, Paul MSc*; Allen, Melissa MPH#; George, Kathleen MPH‡‡; Andrew, Philip RN§§; Zwerski, Sheryl CRNP‖‖; Mofenson, Lynne M. MD¶¶; Jackson, J. Brooks MD, MBA*; for the HPTN 046 Protocol Team

Collapse Box


Background: HPTN 046 compared the efficacy and safety of infant nevirapine (NVP) among HIV-exposed breastfed infants randomized at 6 weeks to 6 months to t NVP or placebo to prevent postnatal infection: we report final 18-month outcomes.

Methods: Randomized, placebo-controlled trial in 4 African countries. Infant diagnostic HIV testing was performed regularly from birth through 18 months. Kaplan–Meier analysis was used to assess 18-month cumulative infant HIV infection, HIV infection/or death, and mortality rates.

Results: Between 6 weeks and 6 months, postnatal HIV infection rates were significantly lower among infants receiving daily NVP from 6 weeks to 6 months 1.1% [95% confidence interval (CI): 0.2% to 1.8%], compared with placebo 2.4% (95% CI: 1.3% to 2.6%), P = 0.049, but not significantly lower thereafter. Eighteen-month postnatal infection rates were low: 2.2% (95% CI: 1.1% to 3.3%) versus 3.1% (95% CI: 1.9% to 4.4%), respectively, P = 0.28. Mortality and HIV infection/death did not differ between arms at any age. Infants of women receiving antiretroviral therapy (ART) for their own health had the lowest 18-month postnatal infection rates (0.5%, 95% CI: 0.0% to 1.1%). However, HIV infection/death rates at 18 months were not significantly different for infants of mothers on ART (3.7%, 95% CI: 1.9% to 5.5%), and infants of mothers with CD4 counts of ≥350 cells per cubic millimeter not receiving ART (4.8%, 95% CI: 2.7% to 6.8%; P = 0.46). There were no differences in adverse events between study arms.

Conclusions: This trial demonstrated early but not late differences in postnatal HIV transmission among infants randomized at age 6 weeks to extended NVP or placebo, underscoring the importance of continued prophylaxis throughout breastfeeding.

© 2014 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.